Unicycive Therapeutics, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

Statements of Mezzanine Equity and Stockholders??? (Deficit) Equity

Statements of Mezzanine Equity and Stockholders’ (Deficit) Equity - USD ($) $ in Thousands	Series B-1 Preferred Stock	Common Stock	Series A-2 Preferred Stock	Series A-2 Prime Preferred Stock	Series B-2 Preferred Stock	Additional Paid-In Capital	Accumulated Deficit	Series A-3 Preferred Stock	Accumulated Other Comprehensive Loss	Total
Balance at Dec. 31, 2023		$ 4				$ 60,728	$ (64,541)			$ (3,809)
Balance (in Shares) at Dec. 31, 2023		3,475,605	43,649
Net loss							(36,729)			(36,729)
Issuance of Series B-1 preferred stock, net of issuance costs	$ 46,187
Issuance of Series B-1 preferred stock, net of issuance costs (in Shares)	50,000
Dividends on Series B-1 preferred stock						(1,095)				(1,095)
Exchange of Series A-2 preferred stock for Series A-2 Prime preferred stock
Exchange of Series A-2 preferred stock for Series A-2 Prime preferred stock (in Shares)			(43,649)	21,388.01
Conversion of Series A-2 Prime preferred stock into common stock		$ 3								3
Conversion of Series A-2 Prime preferred stock into common stock (in Shares)		3,109,755		(15,237.8)
Issuance of Series B-2 preferred stock and common stock upon conversion of Series B-1 preferred stock	$ (46,187)	$ 4				46,179				46,183
Issuance of Series B-2 preferred stock and common stock upon conversion of Series B-1 preferred stock (in Shares)	(50,000)	4,211,800			7,882
Conversion of Series B-2 preferred stock into common stock
Conversion of Series B-2 preferred stock into common stock (in Shares)		488,200			(4,882)
Issuance of common stock for cash, net of issuance costs						524				524
Issuance of common stock for cash, net of issuance costs (in Shares)		97,740
Issuance of common stock for exercise of options						4				4
Issuance of common stock for exercise of options (in Shares)		1,136
Stock-based compensation expense						2,350				2,350
Balance at Dec. 31, 2024		$ 11				108,690	(101,270)			7,431
Balance (in Shares) at Dec. 31, 2024		11,384,236		6,150.21	3,000
Net loss							(26,555)			(26,555)
Issuance of Series A-3 preferred stock upon exercise of warrants						1,496				1,496
Issuance of Series A-3 preferred stock upon exercise of warrants (in Shares)								1,495.8
Conversion of Series A-2 Prime preferred stock into common stock		$ 1								1
Conversion of Series A-2 Prime preferred stock into common stock (in Shares)		792,900		(3,885.21)
Conversion of Series B-2 preferred stock into common stock
Conversion of Series B-2 preferred stock into common stock (in Shares)		300,000			(3,000)
Conversion of Series A-3 preferred stock into common stock
Conversion of Series A-3 preferred stock into common stock (in Shares)		277,000						(1,495.8)
Issuance of common stock for vested restricted stock units
Issuance of common stock for vested restricted stock units (in Shares)		1,000
Issuance of common stock for cash, net of issuance costs		$ 10				45,174				45,184
Issuance of common stock for cash, net of issuance costs (in Shares)		9,310,618
Unrealized loss on available-for-sale securities, net									(1)	(1)
Reverse split share adjustment (in Shares)		48,491
Stock-based compensation expense						2,641				2,641
Balance at Dec. 31, 2025		$ 22				$ 158,001	$ (127,825)		$ (1)	$ 30,197
Balance (in Shares) at Dec. 31, 2025		22,114,245		2,265